Caris Life Sciences shares rise 5.68% intraday after publishing new research and strong Q2 earnings.

Caris Life Sciences, Inc. surged 5.68% intraday, following the release of new research validating the optimal drug sequence for HER2-negative breast cancer patients and the publication of second-quarter financial results showing an 81.3% year-over-year increase in revenue to $181.4 million, exceeding FactSet estimates of $138 million. Additionally, Citigroup raised its price target for the company from $34 to $42, maintaining a buy rating, while TD Cowen increased its target to $38.